Previous Article | Next Article ![]()
Journal of Virology, September 1999, p. 7199-7209, Vol. 73, No. 9
Department of Microbiology and Immunology,
University of Tennessee
Received 19 March 1999/Accepted 27 May 1999
In this report we describe a novel, bipartite vesicular stomatitis
virus (VSV) replication system which was used to study the effect of
mutations in the transcription start sequence on transcript initiation
and 5'-mRNA modifications. The bipartite replication system consisted
of two genomic RNAs, one of which (VSV Vesicular stomatitis virus (VSV) is
an enveloped, nonsegmented minus-strand RNA virus that is considered
the prototype for the Rhabdoviridae family. Because the
genome is in the negative, or noncoding sense, the polymerase must be
packaged in the virion during virus assembly and remain associated with
the ribonucleocapsid core during virus entry and uncoating. The VSV
polymerase is composed of two subunits, the phosphoprotein (P) and the
large subunit (L). Once in the cell cytoplasm, the VSV RNA-dependant
RNA polymerase is responsible for transcribing each of the five genes.
In addition to the initial transcription of viral mRNAs, the polymerase
is responsible for replication of the VSV genomic RNA via synthesis of
a full-length positive-sense replicative intermediate, which is then
used as a template for synthesis of full-length progeny genomes. The
genome as well as the replicative intermediate must be encapsidated by
the nucleocapsid (N) protein to serve as a template for the VSV polymerase.
One of the characteristic features of VSV transcription is that mRNA
synthesis is both sequential and polar (3, 24, 25). Discontinuous transcription is not unique to VSV and occurs with all
nonsegmented, minus-strand RNA viruses; however, there are differences
that are specific for each virus family. During VSV transcription, the
polymerase first transcribes a small (47-nucleotide) RNA called the
leader from the extreme 3' end of the genome, and then each of the five
mRNAs encoding the viral proteins are synthesized in the order they
appear from the 3' end of the genome. For the gene junctions that have
been studied, the downstream gene is transcribed approximately 30%
less than the upstream gene (24), and as a consequence, the
abundance of the five mRNAs also follows the order of genes on the
genome (N > P > M > G > L).
Since the entire VSV life cycle is carried out in the cytoplasm of the
cell, the virus cannot utilize the normal host machinery to carry out
posttranscriptional modifications such as capping and polyadenylation.
Therefore, these activities must be performed by the VSV polymerase
(17, 31, 35, 39, 43). Analysis of the cap structure found on
VSV transcripts indicates that the mechanism responsible for capping
and methylation must differ from the general eukaryotic capping
pathways. Both the Another feature of VSV capping-methylation is that these reactions are
intimately linked with transcription. Presynthesized VSV mRNAs lacking
these modifications are not appropriately modified if added directly to
VSV transcription complexes, whereas typical eucaryotic capping and
methylation occur posttranscriptionally. Precisely how VSV transcript
initiation and capping are coupled remains to be determined. Early
studies demonstrated that short oligonucleotides representing the 5'
end of VSV transcripts can be produced in incomplete (minus UTP) in
vitro reaction mixtures and that the 5' termini of these short
oligonucleotides contained a triphosphate. These results led the
authors to hypothesize that capping occurs following de novo transcript
initiation (10). On the other hand, the unique nature of the
VSV cap suggests that it may arise through an RNA cleavage event.
Recently a model was proposed which suggested that individual
transcripts are "initiated" and capped following a GDP-dependent,
polymerase-mediated cleavage event and that capping occurs as a result
of the GDP-dependent cleavage (44).
In contrast to the uncertain role of the polymerase in the capping of
VSV transcripts, the L protein has a methyltransferase activity, which
has been shown through the analysis of methylation-defective host range
mutants (17-19). During in vitro transcription in the presence of the methyl donor
S-adenosyl-L-methionine (SAM), VSV transcripts
are doubly methylated on the blocking G at the N-7 position and on the
first A at the O-21 position (1) to generate the
cap I structure
(m7G5'ppp5'AmpApCpApG...).
Interestingly, in vivo-generated transcripts exhibit some
heterogeneity in their degree of methylation since the VSV mRNAs can be
further methylated at the first A (N-6 position) and at the second A
(N-6 and O-21 positions)
[m7G5'ppp5'(m)Amp(m)AmpCpApG...]
(31, 39). The additional methylation is thought to be
catalyzed by cytoplasmic host cell enzymes (31) following
VSV-specific methylation at the 2'-O-ribose of the first A
nucleotide (18).
While the addition of a G cap is thought to be obligatorily coupled to
transcription, this does not appear to be the case for methylation. In
vitro transcription in the absence of the methyl donor SAM occurs
efficiently, producing capped yet unmethylated transcripts (1, 16,
19, 35, 51); therefore methylation of the nascent transcript is
not a prerequisite for transcription. Interestingly, during in vitro
transcription in the presence of the methylation inhibitor
S-adenosylhomocystine (SAH), nonmethylated transcripts that
contain large heterogeneous poly(A) tails are generated, indicating
that there may be some connection between modification at the 5' end of
the transcript and polyadenylation (20, 21, 41).
The cis-acting signals that direct the polymerase to
polyadenylate and terminate the upstream mRNA and then to reinitiate transcription at the downstream gene are contained in a set of 23 conserved nucleotides at each VSV gene junction (42). The exact mechanism by which the polymerase executes its multiple activities as it interacts with these cis-acting sequences
has not been elucidated. However, mutational analyses of these
conserved cis-acting signals have provided some insight into
their functional importance (5, 6, 22, 47, 48). The
conserved sequence 3'-AUACU7-5', which is found
at the end of each gene, is critical for both polyadenylation and
termination of VSV transcripts (5, 22). When this sequence
is encountered, the polymerase reiteratively copies, or stutters, over
the seven uridinylate residues to produce a poly(A) tail approximately
150 nucleotides in length (43). Immediately following the
polyadenylation signal are two nontranscribed intergenic nucleotides,
which are usually 3'-GA-5' (38). There is some
evidence that this dinucleotide contributes to the termination signal
of the upstream transcript, because certain nucleotide substitutions
resulted in higher levels of readthrough transcription at the mutated
gene junction (6, 48). Following the intergenic dinucleotide
is the transcription start sequence 3'-UUGUCnnUAC-5' (with n
being any nucleotide). The 5' ends of all VSV mRNAs contain the
complement of this sequence. We have previously shown that the first 3 nucleotides of the VSV 5' transcription start sequence are the most
critical for efficient gene expression because mutations within the
first 3 nucleotides severely reduce the levels of mRNA produced from
the mutant gene in vivo (48).
Mutational analysis of the cis-acting signals described
above were performed with modified and shorter versions of the VSV genome containing a reporter gene or viral genes. One limitation of
these minigenome systems is that the N, P, and L proteins are expressed
in trans and that replication and transcription are carried
out in the presence of vaccinia virus. In addition, mutations that
affect transcription are often identified by measuring the reporter
gene activity or by directly measuring the levels of transcript present
in the minigenome-infected cells. Therefore, mutations that affect
transcript stability cannot be differentiated from those that affect
transcript initiation.
In this report, we describe a novel, bipartite VSV replication system
which was used to further study the functional importance of the
transcription start sequence on transcript initiation and 5'-end mRNA
modifications. The bipartite replication system consisted of two
genomic RNAs, one of which (VSV Expression plasmids and minigenome constructs.
Plasmids
encoding the VSVI N, P, and L proteins have been described
elsewhere (14, 46). The plasmid encoding pBS-VSV
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Transcript Initiation and 5'-End Modifications Are
Separable Events during Vesicular Stomatitis Virus
Transcription
and
Memphis, Memphis, Tennessee 38163
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
G) was a recombinant VSV
genome with the G gene deleted and the other (GFC) contained the G gene
and two non-VSV reporter genes (green fluorescent protein [GFP] and
chloramphenicol acetyltransferase [CAT]). Coinfection of cells with
these two components resulted in high-level virus production and gave
titers similar to that from wild-type-VSV-infected cells. Mutations
were introduced within the first 3 nucleotides of the transcription
start sequence of the third gene (CAT) of GFC. The effects of these
changes on the synthesis and accumulation of CAT transcripts during in
vivo transcription (e.g., in infected cells), and during in vitro
transcription were determined. As we had reported previously (E. A. Stillman and M. A. Whitt, J. Virol. 71:2127-2137, 1997),
changing the first and third nucleotides (NT-1 and NT-3) reduced CAT
transcript levels in vivo to near undetectable levels. Similarly,
changing NT-2 to a purine also resulted in the detection of very small
amounts of CAT mRNA from infected cells. In contrast to the results in vivo, the NT-1C mutant and all of the second-position mutants produced
near-wild-type amounts of CAT mRNA in the in vitro system, indicating
that the mutations did not prevent transcript initiation per se but,
rather, generated transcripts that were unstable in vivo. Oligo (dT)
selection and Northern blot analysis revealed that the transcripts
produced from these mutants did not contain a poly(A)+ tail
and were truncated, ranging in size from 40 to 200 nucleotides. Immunoprecipitation analysis of cDNA-RNA hybrids with an antibody that
recognizes trimethylguanosine revealed that the truncated mutant
transcripts were not properly modified at the 5' end, indicating the
transcripts either were not capped or were not methylated. This is the
first demonstration that transcript initiation and capping/methylation
are separable events during VSV transcription. A model is proposed in
which polymerase processivity is linked to proper 5'-end modification.
The model suggests that a proofreading mechanism exists for VSV and
possibly other nonsegmented minus-strand RNA viruses, whereby if some
transcripts do not become capped during transcription in a normal
infection, a signal is transduced such that the polymerase undergoes
abortive elongation and the defective transcript is terminated
prematurely and subsequently degraded.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
and
phosphates of the 5'-5' triphosphate
linkage of the guanosine cap are contributed by a presumed GDP donor
(1, 2). Therefore, the addition of the 5'-5' guanosine cap
cannot be mediated by a covalent nucleotidyl transfer reaction with GMP
as occurs during typical eukaryotic capping (7). Available
evidence indicates that the P-L polymerase complex mediates the capping
reaction, since mRNAs generated during in vitro transcription reactions with purified virions are efficiently capped. While the L protein does
have some sequence homology to nucleotide binding proteins, it shows no
homology to covalent nucleotidyl transferases (45) and has
never been shown to mediate the capping reaction in trans. Recently it was shown that the VSV polymerase must associate with a
host protein, translation elongation factor 1 (EF-1), to be transcriptionally active (13). The authors proposed that the GTP-GDP binding properties of the
subunit of EF-1 may play a role
in the VSV capping reaction (13).
G) was a recombinant VSV genome with
the G-protein gene deleted and the other (GFC) contained the G protein
gene and two non-VSV reporter genes (green fluorescent protein [GFP]
and chloramphenicol acetyltransferase [CAT]). The effects of
mutations within the 5' start sequence of the CAT gene of GFC were
determined for in vivo transcription (in GFC/
G-infected cells) and
following in vitro transcription. Our data indicate that some mutations
in the 5' transcription start sequence can affect transcript initiation
while others affect 5'-end modifications. Furthermore, our results
suggest that transcript initiation and capping-methylation are
separable events and that the processivity of the VSV polymerase can be
influenced by the addition of 5'-end modifications.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
G was
obtained from C. Robison (37). To generate the wild-type pBS-GFC minigenome cDNA, an AflII-NheI fragment
containing the GFP(S65-T) gene, which was obtained from a minigenome
(pBS-GMF) encoding the VSVI M- and G-protein genes upstream
of the GFP gene, was subcloned into pBS-GMG (46) which had
been digested with the same restriction enzymes. NheI is
located in the 3' untranslated region of the G gene, and
AflII lies within the trailer region of pBS-GMG. Sequences
corresponding to the P-gene transcriptional start site were used to
drive expression of the GFP gene in GMF. In addition, a unique
XhoI site was introduced into the GFP 5' untranslated region
and an SphI site was introduced in the 3' untranslated
region. All of these sequence elements were maintained in the
construction of the GFC cDNA. Following ligation of the AflII-NheI fragment, the resulting minigenome
contained the G-protein gene and the GFP gene flanked by the VSV leader
and trailer regions, respectively. Next, the CAT gene was subcloned
into this G-GFP minigenome between the trailer sequence and the GFP
gene. The GFP-CAT gene junction was derived from the M-G intergenic
region (including 107 nucleotides of the M 3' untranslated region and 29 nucleotides of the G 5' untranslated region). To position the GFP
gene stop codon next to the M gene 3' untranslated region, we designed
an oligonucleotide primer (IG-MUT-2;
5'-CATTCGGCATGCGCTAGTCTAACTTCTAGC-3') that
contained an SphI site (bold) at its 5' end and sequences that overlapped the M 3' untranslated region at its 3' end. To position
the G-protein 5' untranslated region adjacent to the CAT gene
start codon, we designed an oligonucleotide primer (IG-MUT-1; 5'-CTAAGTACAAGTCGACTCTAGAAGTGACGCGTAAACAGATC-3')
which contained a SalI site (underlined) and a
XbaI site (bold italic) at its 5' end and sequences that
overlapped the G 5' untranslated region. These primers were used to
amplify the M gene-G gene intergenic region from pBS-GMMG
(46). The resulting PCR product was digested with
SalI and SphI and used in the three-way ligation
with an AflII-XhoI fragment, which contained the
CAT gene (CAT was previously fused to the trailer in pBS-GMMG-CAT
[a gift from J. Rose, Yale University]), and the G-GFP
minigenome vector, which had been cut with AflII and
SphI to create pBS-GFC-1. SalI and
XhoI have compatible overlapping ends. To replace the G 3'
untranslated sequence (present at the 3' end of the CAT gene and
adjacent to the trailer sequence) with the L gene 3' untranslated
region, an oligonucleotide primer was designed (t-L-CAT;
5'CAC AAGAGGGTCTTAAGGATCAAAGTTTTTTTCATACTTAAAGTTTGGA GTCTCCTCATGATTTTTACGCCCCGCCCTGCCACTC-3')
that contained sequences that overlapped the AflII site in the
trailer region and extended through the polyadenylation signal and the
3' untranslated region of the L gene and then overlapped 21 nucleotides
into the CAT gene coding sequence (bold italic). This primer and the
IG-MUT-2 primer were used to amplify a fragment in which the CAT gene
was fused to the L 3' untranslated region and the trailer. The PCR product was digested with XbaI and AflII and used
to replace the CAT gene in pBS-GFC-1 to create pBS-GFC-2, which was the
parental minigenome for all of the mutants in this study. PCR-amplified regions, except for the CAT gene coding sequence, were sequenced by
using the dideoxynucleotide method and Sequenase.
Recovery of GFC/
G.
Recovery of VSV
G was carried out
essentially as described previously (49). For recovery of
GFC/
G, baby hamster kidney (BHK-21) cells in 35-mm-diameter dishes
were infected with vTF7-3 and transfected with 10 µg of plasmid DNA
containing either wild-type or mutant GFC minigenomes, together with 5, 4, and 1 µg of plasmids encoding the N, P, and L proteins,
respectively, by using TransfectACE as described previously
(40). At 5 h posttransfection, the medium was removed
and the BHK-21 cells were infected with recombinant VSV
G
(approximate multiplicity of infection of 3). At 2 days posttransfection/infection, the medium was collected and vTF7-3 was
removed via filtration through a 0.2-µm syringe filter. This P1
supernatant was then passaged onto fresh BHK-21 cells. At 24 h
postinfection, dishes containing GFC/
G were identified by observing cytopathic effects and GFP expression. To ensure that aberrant viruses
were not recovered, the levels of G and GFP mRNAs expressed from these
viruses were determined by Northern blot analysis and compared to those
of wild-type GFC/
G. For all of the experiments, an unselected
(non-plaque-purified) population of a low-passage virus was used to
reduce the likelihood that a variant with a nonrepresentative
transcription phenotype would be picked inadvertently.
Purification of GFC/
G virus and in vitro transcription
reactions.
Approximately 2.5 × 107 BHK-21 cells
in a 15-cm dish were infected with approximately 350 to 2 × 103 PFU of GFC/
G. Viruses were harvested at 18 to
22 h postinfection and pelleted from the supernatant. Virus
resuspended in TNE (10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA)
was then gradient purified on a 20 to 45% sucrose gradient in TN (10 mM Tris-HCl [pH 7.5], 150 mM NaCl). All viral bands were collected
from the gradient, pelleted, and then resuspended in TNE. The viral
protein concentration was determine by a bicinchoninic acid protein
assay (Pierce). In vitro transcription reactions were carried out
essentially as described previously (34). Gradient-purified
virus (15 µg) was incubated at 30°C for 90 min in 50 mM HEPES (pH
8.0)-100 mM NaCl-5 mM MgCl2-4 mM dithiothreitol-1 mM
each ATP, CTP, GTP, and UTP-0.1% Triton N-101-40 U of RNasin
(Promega)-1 mM SAM (volume, 100 µl).
RNA analysis by primer extension and Northern blot assays.
Following in vitro transcription, the RNA was extracted with
phenol-chloroform and precipitated with 95% ethanol. Poly(A) isolation
was performed with the Oligotex mRNA isolation system (Qiagen). For in
vivo-generated transcripts, BHK-21 cells were infected at an
approximate multiplicity of infection of 1 with either wild-type or
mutant GFC/
G virus. The cells were harvested 6 to 10 h
postinfection, and total RNA was isolated by the method of Chomczynski
and Sacchi (11). For primer extensions, we used oligonucleotide GFP-5 (5'-GTGCCCATTAACATCACCATC-3'),
complementary to a sequence at nucleotides 73 to 94 from the 5'
end of the GFP transcript and oligonucleotide CAT-1
(5'-CAACGGTGGTATATCCAGTG-3') complementary to a sequence at
nucleotides 56 to 75 from the 5' end of the CAT mRNA. These
oligonucleotides were end labeled in a standard kinase reaction as
previously described (48). The primer extension reaction was
carried out essentially as previously described (48), and
the products were analyzed on a 6% sequencing gel. For Northern blot
analysis, in vitro-transcribed RNA was extracted with
phenol-chloroform, precipitated with 95% ethanol, fractionated on a
2% agarose-formaldehyde gel, and transferred to Nytran (Schleicher & Schuell) essentially as described previously (46). GFP- and
CAT-specific RNA species were visualized by using the end-labeled
oligonucleotide probes, GFP-5 and CAT-1, under the conditions described
in reference 46. Band intensities for both primer
extension and Northern blot assays were determined with the Molecular
Dynamics Storm 860 PhosphorImager.
Immunoselection with anti-cap antibody. Total in vitro-generated transcripts were phenol-chloroform extracted, ethanol precipitated, hybridized with at least 5 × 104 cpm of the end-labeled GFP-5 and CAT-1 oligonucleotide primers in 30 µl of hybridization buffer [40 mM piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), [pH 6.8], 1 mM EDTA, 0.4 M NaCl, 80% formamide], which was incubated at 85°C for 5 min, and immediately transferred to 30°C for an overnight incubation. The reverse transcription reaction was performed with SuperScript II (GibcoBRL), an RNase H-negative murine reverse transcriptase. Half of the reaction mixture was brought up in volume to 250 µl with NET (150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100), and RNA-cDNA hybrids were immunoselected with an anti-cap monoclonal antibody, H-20 (a generous gift from Reinhard Luhrmann [8]) essentially as described previously (15). A 1-µl volume of the H-20 ascites was incubated with the capped-RNA-cDNA hybrids for 1 h at 4°C and then incubated with a rabbit anti-mouse immunoglobulin G antibody for 30 min at 4°C. Then 40 µl of a 10.5% (wt/vol) solution of Pansorbin cells (Calbiochem) was added, and complexes were formed at 4°C for 4 h. Following three washes with NET, immunoselected as well as nonimmunoselected RNA-cDNA hybrids were phenol extracted, ethanol precipitated, and fractionated on a 6% polyacrylamide sequencing gel.
| |
RESULTS |
|---|
|
|
|---|
In this study we have continued our investigation into the role of the VSV gene start sequence during transcription. Our previous data from saturation mutagenesis of a VSV gene start sequence indicated that the first three positions of the start sequence are the most critical to attain near-wild-type levels of transcript in vivo. One conclusion was that the mutations within the first 3 nucleotides affected transcript initiation; however, we could not rule out the possibility that transcripts were synthesized but were unstable and quickly degraded. Therefore, we used an in vitro transcription assay which allowed us to analyze the transcripts generated from the various mutants in an environment in which unstable transcripts would not be subjected to degradation.
Recovery of VSV as a bipartite virus.
For the in vitro
transcription assays, we needed to generate relatively large quantities
of recombinant VSV particles containing specific mutations in a gene
start sequence. To this end, we developed a system in which we could
recover a VSV that also contained two non-VSV reporter genes. This
recombinant version of VSV was recovered from cDNA as a bipartite
virus. One genome (VSV
G) contained the full-length VSV genome with
the G gene deleted, while the other genome (GFC) contained the
G-protein gene upstream of two non-VSV reporter genes (GFP and CAT)
(Fig. 1). These miniviruses complemented each other; therefore, coinfection of cells in culture resulted in
propagation of the bipartite virus (GFC/
G). These bipartite viruses
were grown to high titers and gradient purified. Northern blot analysis
of genomic RNA isolated from purified GFC/
G virus confirmed that
both genomic RNA species were present in approximately the same amounts
(data not shown).
|
G were kept in the same gene order and location as found
in wild-type VSV to ensure that these proteins were expressed at the
appropriate levels. The GFP and CAT genes were positioned as the second
and third cistrons, respectively, on the GFC genome and therefore were
expressed at sufficiently high levels for transcript analysis. This
bipartite-virus system also allowed us to make mutations that
dramatically reduced transcription at the GFP-CAT gene junction without
affecting the growth of the bipartite virus, since these genes were not
required for viral growth and were not upstream of any other essential
VSV genes. A total of 10 recombinant bipartite viruses that contained
either the wild-type start sequence or nucleotide changes within the start sequence of the CAT reporter gene were generated.
Analysis of bipartite virus transcripts made in vivo.
Previously, saturation mutagenesis analysis was performed within the G
gene 5' start sequence in the context of an M- and G-expressing
minigenome (48). To determine if the same mutations in the
CAT gene 5' start sequence had a similar effect on the level of CAT
transcripts during a GFC/
G infection, total RNA from wild-type- or
mutant-GFC/
G-infected cells was analyzed by a primer extension assay
to detect GFP and CAT transcripts (Fig. 2, lanes V). The
GFP-specific primer was complementary to nucleotides 73 to 94 of the
GFP mRNA, and the CAT-specific primer was complementary to nucleotides
56 to 75 of the CAT mRNA. The relative level of CAT mRNA expressed,
which is defined as the ratio of CAT to GFP primer extension products,
is shown in the bar graph above each respective lane. For in
vivo-generated RNA, the major product mapped to the first nucleotide of
the 5' mRNA start site for both CAT mRNA and GFP mRNA. The 5' start
sites were identified by migration of the primer extension products to
the appropriate position relative to the sequencing ladder (examples
shown in the right-hand-most lane of panels B and C only). The results
indicated that the level of CAT mRNA expressed by each of the mutants
during in vivo transcription was similar to the level of G mRNA
expressed in the previous minigenome system (48) when
mutants with the same nucleotide changes were compared. Specifically,
nucleotide changes within the first 3 nucleotides of the start sequence
severely decreased the amount of the corresponding mRNA, except for the
NT-2C mutation, in which there was only a moderate decrease in the
level of the corresponding transcript.
|
Mutations in the start sequence affect postinitiation events in
vitro.
To determine the level of CAT mRNA expressed from wild-type
GFC/
G and each of the mutants during in vitro transcription, we used
primer extension and the same GFP- and CAT-specific primers as
described above. The RNA populations examined included total (unfractionated) RNA (Fig. 2, lanes T) as well as both polyadenylated [oligo(dT) bound; lanes B] and nonpolyadenylated (unbound; lanes U)
RNAs. Again, the relative level of CAT mRNA expressed and detected via
primer extension from the wild-type virus and each of the mutants was
determined by calculating the ratio of CAT product to GFP product as
shown in the bar graph above each respective lane. For wild-type virus
and each of the mutants, the relative amount of poly(A) CAT transcript
generated in vitro was similar to the amount of CAT mRNA isolated from
cells during in vivo transcription (compare lanes B to lanes V for each
of the viruses). Therefore, the amount of polyadenylated RNA expressed
by each of the mutants during in vitro transcription corresponded to
the amount of stable CAT transcripts isolated from infected cells in vivo.
Mutations in the VSV start sequence affect the processivity of the
polymerase.
To determine the length of the nonpolyadenylated
transcripts, we used Northern blot analysis to detect the CAT and GFP
RNA species produced during an in vitro transcription reaction for wild-type GFC/
G and each mutant virus (Fig.
3A). The same oligonucleotide probes that
were used in the primer extension assay were used to detect either
GFP-specific RNA species (Fig. 3A, top, GFP mRNA only) or CAT specific
species (Fig. 3A, bottom). The CAT-specific probe also detected the
dicistronic GFP-CAT mRNA as well as the GFC replicative intermediate
(Fig. 3A, bottom). The ratio of full-length CAT mRNA to GFP mRNA was
determined for each mutant (results not shown). The results indicated
that the relative level of full-length CAT mRNA expressed by each
mutant corresponded to (i) the amount of polyadenylated RNA produced
during in vitro transcription and (ii) the amount of stable CAT
transcripts isolated from infected cells in vivo.
|
G and the NT-1C mutant virus was examined by Northern blot
analysis with three different CAT-specific oligonucleotide probes that
were each complementary to a different region of the CAT gene (Fig.
3B). The probe that was complementary to nucleotides 11 to 41 detected
a smear of CAT RNA that contained shorter RNAs than did the probe that
was complementary to nucleotides 56 to 75, while the probe that was
complementary to nucleotides 247 to 269 did not detect the truncated
CAT species. These results indicated that the truncated species did not
result from random degradation of the CAT transcript in vitro; however,
we cannot exclude the possibility that they represent specific products arising from 3'-end degradation. Second, these results showed that the
truncated CAT mRNAs were heterogeneous in size and ranged from
approximately 40 to less than 247 nucleotides.
The primer extension data and the Northern blot data both indicated
that the major effect of third-position mutations was on transcript
initiation. These assays were performed with an oligonucleotide probe
that was complementary to nucleotides 56 to 75; therefore, RNA species
shorter than 56 to 75 nucleotides would not be detected. To ascertain
if CAT mRNA was indeed initiated from the NT3 mutants but was not
detected by the probe, total in vitro-generated RNA from the wild type
and NT3 mutants was hybridized with a labeled oligonucleotide probe
complementary to nucleotides 11 to 41. There was not a significant
increase in the level of the truncated CAT mRNA when this
oligonucleotide was used as a probe (data not shown). This result
suggested that while the NT3 mutants did produce a small amount of the
truncated mRNA species, the major effect of the third-position changes
was on transcript initiation.
Mutations in the start sequence inhibit capping or methylation by the polymerase. In addition to transcription, the polymerase is responsible for capping and methylating the 5' end of nascent transcripts (17, 19, 31, 35, 39). This capping and methylation occurs concomitantly during transcription; therefore the conserved sequences at the start site could potentially serve as a signal for these processes.
To determine if the nucleotide changes in the CAT start sequence affected the ability of the polymerase to cap and/or methylate the nascent CAT transcript, we used a monoclonal antibody specific for trimethyl guanosine (8). This antibody also recognizes the methylated cap structure at the 5' end of transcripts and can be used to immunoprecipitate capped mRNAs. First, total RNA from in vitro transcription reactions with either wild-type or mutant viruses was used in primer extension assays with the CAT- and GFP-specific primers described above, together with an RNase H-minus reverse transcriptase to prevent degradation of the RNA in the cDNA-RNA complex. The cDNA-RNA hybrid complexes were then immunoprecipitated. The products of both nonimmunoprecipitated and immunoprecipitated primer extension reactions were visualized on a sequencing gel (Fig. 4). The GFP mRNA served as an internal, positive control, since this transcript should be capped and methylated normally. For the wild-type virus (lanes 13 and 14 or lanes 15 and 16), the CAT-to-GFP ratios for both the nonimmunoprecipitated and the immunoprecipitated cDNAs were similar, indicating that both the GFP and CAT mRNAs were capped and methylated to the same extent. However, the relative amounts of CAT transcript that were immunoprecipitated from the mutants were either significantly decreased or undetectable (lanes 2, 4, 6, 10, 12, 18, 20, and 22). These data indicated that the majority of the CAT transcripts generated in vitro from the mutants were not capped and/or methylated. Therefore, mutations within the first 3 nucleotides of the CAT 5' start sequence affected the ability of the polymerase to cap and/or methylate the nascent transcript.
|
Lack of methylation does not induce premature transcript
termination.
It has been well documented in other in vitro
transcription studies that the absence of SAM during VSV in vitro
transcription results in full-length transcripts that are capped but
not methylated (4, 19, 35), suggesting that transcription is
not affected by the lack of methylation. To determine if this result is
observed during GFC/
G in vitro transcription, transcripts were
generated in vitro in either the presence or absence of SAM for the
wild-type, NT-1C, and NT-2C viruses. Northern blot analysis with GFP-
and CAT-specific probes showed that full-length GFP and CAT mRNAs were
generated during wild-type GFC/
G transcription in the absence or
presence of SAM (Fig. 5A, lanes 1 and 2). Full-length GFP mRNAs were
also generated in the absence or presence of SAM during in vitro
transcription of the NT-1C and NT-2C mutant viruses (Fig. 5A, top, lanes 3 to 6); however, the
profile of the CAT transcripts differed slightly between the
transcripts generated in the absence or presence of SAM. For the NT-1C
mutant virus, truncated CAT mRNA was synthesized in the absence of SAM
but full-length CAT mRNA was undetectable (compare lanes 3 and 4). In
contrast, full-length CAT mRNAs were synthesized from the NT-2C mutant
virus in both the presence and absence of SAM, but very little
truncated CAT mRNA was produced in the absence of SAM (compare lanes 5 and 6). While the implications of these results are not known, it is
clear that some mutations in the 5' start sequence have a greater
effect on the polymerase in the absence of a methyl donor during in
vitro transcription.
|
| |
DISCUSSION |
|---|
|
|
|---|
To study the role of the 5' start sequence during VSV
transcription, we used a reverse genetics system in which VSV was
recovered from cDNA as a bipartite virus and one of the genomes encoded two reporter genes, GFP and CAT. This bipartite-virus system has several advantages over the other existing reverse genetic systems. First, this recombinant virus expresses all of the VSV proteins and
does not require helper VSV proteins to be provided in trans for replication and transcription, as is necessary in the minivirus systems that have been used previously (5, 6, 22, 47, 48).
Therefore, transcription, replication, and, ultimately, virus
propagation are not limited by the efficiency of plasmid transfections.
Second, while the vaccinia virus-T7 RNA polymerase system is used
initially to recover the virus, the vaccinia virus is removed after the
first passage since GFC/
G is self-propagating. This eliminates
potential problems associated with the presence of cytoplasmic capping
enzymes encoded by vaccinia virus, since the activities of these
enzymes may mask the effects of mutations that affect VSV capping.
Third, this system is especially suited for the analysis of the VSV
transcription signals, since mutations can be made at the GFP-CAT gene
junction without affecting the expression of essential VSV genes.
Because high-titer supernatants and large quantities of the bipartite
virus can be produced and purified, the effect of mutations can easily
be examined both in vivo and in vitro.
The results of this study confirmed our previous conclusions that the first 3 nucleotides of the 5' start sequence are critical for gene expression in vivo. Interestingly, mutations within the first 3 nucleotides of the start sequence did not always result in the same phenotype during in vitro transcription. The mutant viruses examined in this study fell into two groups when the amount of CAT mRNA generated in vitro was determined. The primary effect observed for the first group (NT-1G, NT-1A, and all third-position mutants) was on transcription initiation, since the amount of total CAT transcript generated in vitro was severely reduced compared to wild-type levels. In contrast, transcript initiation for the second group (NT-1C and all second-position mutants) ranged from 50% to near-wild-type levels. However, the majority of these mRNAs were not polyadenylated. These data show that the first 3 nucleotides of the start sequence play a role in transcript initiation as well as in postinitiation events during in vitro transcription and that specific nucleotide positions in the 5' start sequence have differing effects on these events.
Further characterization of the mutant CAT transcripts lacking a poly(A) tail revealed that they did not contain the appropriate 5' cap structure and were not fully elongated, suggesting that proper capping and/or methylation is important for polymerase processivity. The relative amount of mature CAT mRNA (i.e., capped, methylated, and polyadenylated) that was generated in vitro from each of the mutants correlated with the amount of CAT transcripts produced in vivo. Therefore, the results of the in vitro transcription assays probably parallel the transcriptional events that occur in vivo. For example, we predict that transcripts from the NT-1C and all NT-2 mutants are initiated in vivo but quickly become degraded due to the lack of an appropriate cap structure, the incomplete elongation, and the lack of a poly(A) tail. To our knowledge, this is the first time that the 5' start sequence of a negative-strand RNA virus has been shown to play a role not only in transcript initiation but also in capping and/or methylation and polymerase processivity.
The data from our study may also explain the results obtained by Luk et
al. (30), who used primer extension assays to map the start
site of the L protein transcript in VSVNJ-infected cells, as well as after transcription in vitro. The G-L intergenic junction contains an extra 19 nucleotides following the conserved 3'-GA-5' dinucleotide. Analysis of in vivo-generated transcripts indicated that
only the consensus start sequence was used, whereas it appeared that in
vitro-generated transcripts were initiated at two distinct sites, one
following the intergenic dinucleotide at a nonconsensus start and one
at the consensus start sequence. Data obtained with a GFC/
G virus
that contains this variant intergenic region at the GFP-CAT gene
junction indicated that transcripts that were initiated at a
nonconsensus start sequence during in vitro transcription were not
polyadenylated and were not detected in RNA samples isolated from
infected cells (data not shown). Therefore, we speculate that during a
wild-type VSVNJ infection, transcripts are initiated at the
nonconsensus start site but they do not have the appropriate postinitiation modifications and are quickly degraded.
At this point, we have not been able to definitively determine whether
the nucleotide changes in the 5' start sequence affect the addition of
the 5'-GpppA cap or if they affect only methylation. It has
been previously documented for wild-type VSV that full-length, nonmethylated transcripts are synthesized during in vitro transcription reactions in the absence of a methyl donor (4, 19, 35). We
have also shown here that in vitro transcription of wild-type GFC/
G
proceeds normally in the absence of a methyl donor and that these
transcripts are not efficiently recognized by an antibody specific for
trimethyl guanosine. These data suggest that methylation is not
required for synthesis of mature mRNAs; therefore, we favor the
hypothesis that the major defect of the truncated CAT transcripts is
the lack of a 5'-GpppA cap. However, in vitro transcription of two mutant GFC/
G viruses indicated that in the absence of a
methyl donor, the VSV polymerase synthesizes slightly different amounts
of full-length and truncated CAT transcripts. Possibly the nucleotide
change in the 5' start sequence in addition to the lack of a methyl
donor further affects polymerase processivity. Experiments to determine
if these truncated CAT transcripts are capped but not methylated are
under way.
The second defect of these transcripts was that they were not fully elongated, indicating that mutations in the 5' start sequence also affect the processivity of the polymerase. Whether this is a direct effect on polymerase processivity or a secondary effect resulting from incomplete modification of the 5' end by capping and/or methylation requires additional research. Interestingly, the majority of the truncated CAT transcripts were heterogeneous in length, from 41 to less than 247 nucleotides, which corresponds to the first quarter of the CAT gene. These results suggest that the abortive elongation event probably occurs within a window and is not a random event occurring at all positions along the CAT gene (i.e., truncated transcripts do not range in size up to the length of the CAT gene). Presumably, transcripts that reach this critical length are completely elongated and subsequently polyadenylated.
The mechanism by which these mutations affect VSV polymerase processivity is not known, but there are various mechanisms by which transcriptional elongation is controlled during prokaryotic, eukaryotic, and viral transcription (52). The occurrence of mutations at the 5' end of nascent VSV transcripts affecting downstream polymerase processivity is reminiscent of the Tat-TAR (Tat activation response element) interaction during human immunodeficiency virus (HIV) transcription. The interaction of the 5' end of nascent HIV transcripts containing the TAR sequence with the HIV transactivating protein, Tat, increases polymerase processivity. Mutations in the TAR sequence alter the interaction with Tat and other cellular transcription elongation factors and ultimately affect the ability of the polymerase to efficiently elongate the transcript (26, 28, 29). In another example, the Gre-A and Gre-B proteins have been shown to stimulate a cleavage reaction in which 2 to 10 nucleotides are removed from the 3' end of the nascent transcript (9). Presumably, this cleavage reaction prevents the formation of arrested transcription complexes and promotes transcript elongation (27). For respiratory syncytial virus, it was recently demonstrated that the M2 (ORF1) protein functions as a transcription elongation factor during transcription (12). While regulation of transcriptional elongation to control gene expression is commonly used, the effects on VSV polymerase processivity observed in this study are not indicative of a mechanism for regulation of transcript levels, since the mutations we have made have not been found in natural VSV isolates. Instead, the mechanism of abortive elongation may have evolved to prevent the synthesis of mRNAs that have not been properly modified at the 5' end.
The findings of this study have provided new insights into the events that occur during VSV transcription initiation and elongation. One of the interesting observations is that the inability to correctly modify the 5' end of the nascent transcript correlates with an increase in abortive elongation. One possible model to account for this observation is that following initiation the 5' end of the nascent transcript maintains contact with the polymerase (Fig. 6). Modification of the 5' end of the transcript may occur during transcription of the first 200 nucleotides. Once capping and methylation is completed, the 5' end of the transcript is released, which may eliminate steric hindrance or induce a conformational change in the polymerase so that it can proceed along the template. In the start site mutants, the polymerase does not properly modify the 5' end of the nascent transcript, and so the appropriate signals are not sent, which causes the polymerase to stall and terminate transcription prematurely.
|
A thorough understanding of the mechanism of VSV transcription requires an understanding of the spatially and temporally connected transcriptional events that occur at the intergenic junctions. Other than the cis-acting signals which direct these events, there are additional considerations that must be taken into account when generating models to describe VSV transcription. For example, how does the polymerase interact with an encapsidated helical template? Recently, it has been demonstrated that certain genetic elements must be positioned along the same face of the helical nucleocapsid at the 3' end of the paramyxovirus simian virus 5 antigenome to generate a functional antigenomic promoter (32). Similar results have also been demonstrated for another paramyxovirus, Sendai virus, in which a hexamer motif, (GNNNNN)3, found at nucleotides 79 to 96 appears to be critical for both the genome and antigenome promoter function (50). While these results suggest that the helical nature of the encapsidated template affects how the polymerase interacts with the genome, the exact nature of the polymerase interaction with an encapsidated helical template remains very poorly understood. These studies, in addition to earlier experiments examining leader-polymerase interactions (23), indicate that the polymerase may contact a large area of the template and that downstream transcriptional events could therefore affect upstream events. The recent evidence that the cellular elongation factor, EF-1, is required for transcription in vitro (13) and the evidence that phosphorylation and multimerization states of the P protein modulate the transcriptional and replicative activities of the polymerase (33, 36) contribute to the emerging models of transcription for VSV as well as for other minus-strand RNA viruses.
| |
ACKNOWLEDGMENTS |
|---|
We are indebted to Reinhard Lührmann (Institut für
Molekularbiologie und Tumorforschung, Universität Marburg) for
the generous gift of the H-20 ascites fluid containing the
antitrimethylguanosine specific monoclonal antibody, and we thank
Daniel Kolakofsky (University of Geneva) for directing us to him. We
also acknowledge Martin Chalfie (Columbia University) for providing the
original GFP cDNA and Jack Rose (Yale University School of Medicine)
for providing the GMMG-CAT plasmid. The technical assistance
of Carolyn Matthews, Felicia Waller, Zorina Bowen, and Gipsy Majumdar
is greatly appreciated. Oligonucleotides were synthesized by the
Molecular Resource Center at UT
Memphis. The PhosphorImager was made
available also through the Molecular Resource Center at UT
Memphis.
This work was supported by NIH grant GM-53726 (to M.A.W.).
| |
FOOTNOTES |
|---|
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of Tennessee
Memphis, 858 Madison Ave., Memphis, TN 38163. Phone: (901) 448-4634. Fax: (901)
448-8462. E-mail: mwhitt{at}utmem.edu.
Present address: Department of Microbiology and Immunology,
Stanford University School of Medicine, Stanford, CA 94305.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abraham, G., D. Rhodes, and A. K. Banerjee. 1975. 5'-terminal structure of methylated mRNA synthesized in vitro by vesicular stomatitis virus. Cell 5:51-58[Medline]. |
| 2. | Abraham, G., D. Rhodes, and A. K. Banerjee. 1975. Novel initiation of RNA synthesis in vitro by vesicular stomatitis virus. Nature (London) 255:37-40[Medline]. |
| 3. |
Ball, L. A., and C. N. White.
1976.
Order of transcription of genes of vesicular stomatitis virus.
Proc. Natl. Acad. Sci. USA
73:442-446 |
| 4. |
Banerjee, A. K.
1980.
5'-terminal cap structure in eukaryotic messenger ribonucleic acids.
Microbiol. Rev.
44:175-205 |
| 5. | Barr, J. N., S. P. Whelan, and G. W. Wertz. 1997. cis-acting signals involved in termination of vesicular stomatitis virus mRNA synthesis include the conserved AUAC and the U7 signal for polyadenylation. J. Virol. 71:8718-8725[Abstract]. |
| 6. | Barr, J. N., S. P. Whelan, and G. W. Wertz. 1997. Role of the intergenic dinucleotide in vesicular stomatitis virus RNA transcription. J. Virol. 71:1794-1801[Abstract]. |
| 7. | Bisaillon, M., and G. Lemay. 1997. Viral and cellular enzymes involved in synthesis of mRNA cap structure. Virology 236:1-7[Medline]. |
| 8. | Bochnig, P., R. Reuter, P. Bringmann, and R. Luhrmann. 1987. A monoclonal antibody against 2,2,7-trimethylguanosine that reacts with intact, class U, small nuclear ribonucleoproteins as well as with 7-methylguanosine-capped RNAs. Eur. J. Biochem. 168:461-467[Medline]. |
| 9. | Borukhov, S., V. Sagitov, and A. Goldfarb. 1993. Transcript cleavage factors from E. coli. Cell 72:459-466[Medline]. |
| 10. |
Chanda, P. K., and A. K. Banerjee.
1981.
Identification of promoter-proximal oligonucleotides and a unique dinucleotide, pppGpC, from in vitro transcription products of vesicular stomatitis virus.
J. Virol.
39:93-103 |
| 11. | Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159[Medline]. |
| 12. |
Collins, P. L.,
M. G. Hill,
J. Cristina, and H. Grosfeld.
1996.
Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus.
Proc. Natl. Acad. Sci. USA
93:81-85 |
| 13. |
Das, T.,
M. Mathur,
A. K. Gupta,
G. M. Janssen, and A. K. Banerjee.
1998.
RNA polymerase of vesicular stomatitis virus specifically associates with translation elongation factor-1 alphabetagamma for its activity.
Proc. Natl. Acad. Sci. USA
95:1449-1454 |
| 14. | Fredericksen, B. L., and M. A. Whitt. 1995. Vesicular stomatitis virus glycoprotein mutations that affect membrane fusion activity and abolish virus infectivity. J. Virol. 69:1435-1443[Abstract]. |
| 15. |
Garcin, D., and D. Kolakofsky.
1990.
A novel mechanism for the initiation of Tacaribe arenavirus genome replication.
J. Virol.
64:6196-6203 |
| 16. |
Hefti, E., and D. H. L. Bishop.
1976.
The 5' sequence of VSV in vitro transcription product RNA (+/ SAM).
Biochem. Biophys. Res. Commun.
68:393-400[Medline].
|
| 17. | Hercyk, N., S. M. Horikami, and S. A. Moyer. 1988. The vesicular stomatitis virus L protein possesses the mRNA methyltransferase activities. Virology 163:222-225[Medline]. |
| 18. | Horikami, S. M., F. De Ferra, and S. A. Moyer. 1984. Characterization of the infection of permissive and nonpermissive cells by host range mutants of vesicular stomatitis virus defective in RNA methylation. Virology 138:1-15[Medline]. |
| 19. |
Horikami, S. M., and S. A. Moyer.
1982.
Host range mutants of vesicular stomatitis virus defective in in vitro RNA methylation.
Proc. Natl. Acad. Sci. USA
79:7694-7698 |
| 20. |
Hunt, D. M.
1989.
Effect of analogues of S-adenosylmethionine on in vitro polyadenylation by vesicular stomatitis virus.
J. Gen. Virol.
70:535-542 |
| 21. |
Hunt, D. M.,
R. Mehta, and K. L. Hutchinson.
1988.
The L protein of vesicular stomatitis virus modulates the response of the polyadenylic acid polymerase to S-adenosylhomocysteine.
J. Gen. Virol.
69:2555-2561 |
| 22. |
Hwang, L. N.,
N. Englund, and A. K. Pattnaik.
1998.
Polyadenylation of vesicular stomatitis virus mRNA dictates efficient transcription termination at the intercistronic gene junctions.
J. Virol.
72:1805-1813 |
| 23. |
Isaac, C. L., and J. D. Keene.
1982.
RNA polymerase-associated interactions near template promoter sequences of defective interfering particles of vesicular stomatitis virus.
J. Virol.
43:241-249 |
| 24. | Iverson, L. E., and J. K. Rose. 1981. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23:477-484[Medline]. |
| 25. |
Iverson, L. E., and J. K. Rose.
1982.
Sequential synthesis of 5'-proximal vesicular stomatitis virus mRNA sequences.
J. Virol.
44:356-365 |
| 26. | Kao, S. Y., A. F. Calman, P. A. Luciw, and B. M. Peterlin. 1987. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-493[Medline]. |
| 27. | Kassavetis, G. A., and E. P. Geiduschek. 1993. RNA polymerase marching backward. Science 259:944-945[Medline]. |
| 28. |
Kato, H.,
H. Sumimoto,
P. Pognonec,
C. H. Chen,
C. A. Rosen, and R. G. Roeder.
1992.
HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors.
Genes Dev.
6:655-666 |
| 29. | Laspia, M. F., A. P. Rice, and M. B. Mathews. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:283-292[Medline]. |
| 30. | Luk, D., P. S. Masters, D. S. Gill, and A. K. Banerjee. 1987. Intergenic sequences of the vesicular stomatitis virus genome (New Jersey serotype): evidence for two transcription initiation sites within the L gene. Virology 160:88-94[Medline]. |
| 31. | Moyer, S. A., and A. K. Banerjee. 1976. In vivo methylation of vesicular stomatitis virus and its host cell messenger RNA species. Virology 70:339-351[Medline]. |
| 32. |
Murphy, S. K.,
Y. Ito, and G. D. Parks.
1998.
A functional antigenomic promoter for the paramyxovirus simian virus 5 requires proper spacing between an essential internal segment and the 3' terminus.
J. Virol.
72:10-19 |
| 33. | Pattnaik, A. K., L. Hwang, T. Li, N. Englund, M. Mathur, T. Das, and A. K. Banerjee. 1997. Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication. J. Virol. 71:8167-8175[Abstract]. |
| 34. | Peluso, R. W., J. C. Richardson, J. Talon, and M. Lock. 1996. Identification of a set of proteins (C' and C) encoded by the bicistronic P gene of the Indiana serotype of vesicular stomatitis virus and analysis of their effect on transcription by the viral RNA polymerase. Virology 218:335-342[Medline]. |
| 35. |
Rhodes, D., and A. K. Banerjee.
1976.
5'-terminal sequence of vesicular stomatitis virus genome RNA.
J. Virol.
17:33-42 |
| 36. | Richardson, J. C., and R. W. Peluso. 1996. Inhibition of VSV genome RNA replication but not transcription by monoclonal antibodies specific for the viral P protein. Virology 216:26-34[Medline]. |
| 37. | Robison, C. Personal communication. |
| 38. | Rose, J. K. 1980. Complete intergenic and flanking gene sequences from the genome of vesicular stomatitis virus. Cell 19:415-421[Medline]. |
| 39. |
Rose, J. K.
1975.
Heterogeneous 5'-terminal structures occur on vesicular stomatitis virus mRNAs.
J. Biol. Chem.
250:8098-8104 |
| 40. | Rose, J. K., L. Buonocore, and M. A. Whitt. 1991. A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. BioTechniques 10:520-525[Medline]. |
| 41. |
Rose, J. K.,
H. F. Lodish, and M. L. Brock.
1977.
Giant heterogeneous polyadenylic acid on vesicular stomatitis virus mRNA synthesized in the presence of S-adenosylhomocysteine.
J. Virol.
21:683-693 |
| 42. | Schnell, M. J., L. Buonocore, M. A. Whitt, and J. K. Rose. 1996. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70:2318-2323[Abstract]. |
| 43. |
Schubert, M.,
J. D. Keene,
R. C. Herman, and R. A. Lazzarini.
1980.
Site on the vesicular stomatitis virus genome specifying polyadenylation at the end of the L gene.
J. Virol.
34:550-559 |
| 44. | Shuman, S. 1997. A proposed mechanism of mRNA synthesis and capping by vesicular stomatitis virus. Virology 227:1-6[Medline]. |
| 45. | Shuman, S., and B. Schwer. 1995. RNA capping enzyme and DNA ligase: a superfamily of covalent nucleotidyl transferases. Mol. Microbiol. 17:405-410[Medline]. |
| 46. | Stillman, E. A., J. K. Rose, and M. A. Whitt. 1995. Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins. J. Virol. 69:2946-2953[Abstract]. |
| 47. |
Stillman, E. A., and M. A. Whitt.
1998.
The length and sequence composition of vesicular stomatitis virus intergenic regions affect mRNA levels and the site of transcript initiation.
J. Virol.
72:5565-5572 |
| 48. | Stillman, E. A., and M. A. Whitt. 1997. Mutational analyses of the intergenic dinucleotide and the transcriptional start sequence of vesicular stomatitis virus (VSV) define sequences required for efficient termination and initiation of VSV transcripts. J. Virol. 71:2127-2137[Abstract]. |
| 49. |
Takada, A.,
C. Robison,
H. Goto,
A. Sanchez,
K. G. Murti,
M. A. Whitt, and Y. Kawaoka.
1997.
A system for functional analysis of Ebola virus glycoprotein.
Proc. Natl. Acad. Sci. USA
94:14764-14769 |
| 50. |
Tapparel, C.,
D. Maurice, and L. Roux.
1998.
The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication.
J. Virol.
72:3117-3128 |
| 51. |
Toneguzzo, F., and H. P. Ghosh.
1976.
Characterization and translation of methylated and unmethylated vesicular stomatitis virus mRNA synthesized in vitro by ribonucleoprotein particles from vesicular stomatitis virus-infected cells.
J. Virol.
17:477-491 |
| 52. | Wright, S. 1993. Regulation of eukaryotic gene expression by transcriptional attenuation. Mol. Biol. Cell 4:661-668[Medline]. |
This article has been cited by other articles: